SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) Total Current Liabilities

As of the most recent data (September 2026), BCYPU shows a total current liabilities of $15M. That compares with $11M in the prior-year period — up 37.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, BCYPU's total current liabilities is now $15M (was $11M) — a 37.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) is outperforming or lagging.

Tracking BCYPU's total current liabilities over time shows whether SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt) is scaling, shrinking, or reshaping that part of the business. The current reading is $15M That compares with $11M in the prior-year period — up 37.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has SAB Biotherapeutics- Unit (1 Ordinary share & 1/2 Wrt)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $15M) with ownership activity and broader fundamentals.